Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis.
Sulfamethoxazole (SMX) is an important antibiotic in the management of patients with cystic fibrosis, but allergic reactions may develop thus restricting therapy. The aim of this study was to utilize drug (metabolite) antigens to diagnose SMX-mediated allergic reactions in patients with cystic fibrosis. Lymphocytes from 2/12 allergic patients were stimulated to proliferate strongly with the SMX metabolite nitroso SMX (SMX-NO). In contrast, responses to SMX were weak. The introduction of an antigen-driven T-cell enrichment step prior to the analysis of proliferation increased the sensitivity of the assay. SMX-NO responses were detected with lymphocytes from all patients with cutaneous signs.
Lavergne
Sidonie N
SN
MRC Centre for Drug Safety Science, Department of Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L693GE, England.
Whitaker
Paul
P
Peckham
Daniel
D
Conway
Steve
S
Park
B Kevin
BK
Naisbitt
Dean J
DJ
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000276:immunology* / Q000378:metabolism / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000150:complications / Q000276:immunology*; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis* / Q000209:etiology; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000276:immunology* / Q000378:metabolism / Q000627:therapeutic use; D055815:Young Adult
D000890:Anti-Infective Agents; D013420:Sulfamethoxazole